Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study |
| |
| Institution: | 1. Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France;2. Department of Biostatistics and Epidemiology, Gustave Roussy, INSERM U1018, CESP, Université Paris-Saclay, Villejuif, F-94805, France;3. Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK;4. Edinburgh Urological Cancer Group, University of Edinburgh, Western General Hospital, Edinburgh, UK;5. Academic Urology Group, University of Cambridge, Addenbrooke''s Hospital, Cambridge, UK;6. Medical Oncology, The Royal Marsden Hospital, Fulham Road, London, UK;7. Medical Oncology, Centre Léon Bérard, Lyon, France;8. Medical Oncology, Istituto Toscano Tumori, Pisa, Italy;9. Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy;10. Department of Medical Oncology, Institute of Cancer Studies & Pathology University of Leeds, Leeds, UK;11. Medical Oncology, Hôpital Henri Mondor Créteil AP-HP, France;12. Medical Oncology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France;13. Department of Urology, CHU de Bordeaux, Bordeaux, France;14. Faculty of Medicine and Health Sciences Macquarie University, Sydney, Australia;15. Department of Urology, CHU de Rennes, Rennes, France;p. Medical Oncology, Centre Eugène Marquis, Rennes, France;q. Medical Oncology, CHU d''Angers Angers, France;r. Department of Urology, CHU Dupuytren, Limoges, France;s. Department of Urology, CHU Charles Nicolle, Rouen, France;t. Medical Oncology, Institut Paoli-Calmettes, Marseille, France;u. Medical Oncology, Hôpital Bichat Paris, France;v. Medical Oncology, Hôpital Saint Louis Paris, France;w. Medical Oncology, Hopital privée la Louvière Lille, France;x. Medical Oncology, Centre Oscar Lambret Lille, France;y. Medical Oncology, Institut René Gauducheau Saint Herblain, France;z. Medical Oncology, Centre Hospitalier de Vendée La Roche sur Yon, France;11. Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy;1. Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China;2. Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China;1. Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska, Prague, Czech Republic;2. Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic;3. Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic;4. Department of Oncology, General University Hospital and Charles University First Faculty of Medicine, Prague, Czech Republic;5. Department of Oncology, Motol University Hospital and Second Faculty of Medicine, Charles University, Prague, Czech Republic;6. Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic;7. Department of Oncology, University Hospital, Pilsen, Czech Republic;8. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic;9. University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic;1. Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy;2. Department of Medical Oncology, University Hospital, Ancona, Italy;3. Skin Cancer Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy;4. Biostatistic and Clinical Trials Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy;1. Department of Urology, Sint Lucas Andreas Hospital, Amsterdam, The Netherlands;2. Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands;3. Department of Urology, Sint Antonius Hospital, Nieuwegein, The Netherlands;4. Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;5. Department of Medical Oncology, The Netherlands Cancer Institute Amsterdam, The Netherlands;6. Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;7. Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;1. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA;2. Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain;3. Deparment of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA;4. Department of Oncology, Aarhus University Hospital, Aarhus, Denmark;5. Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France;6. Department of General Medical Oncology and Laboratory for Experimental Oncology, University Hospitals Leuven, Leuven, Belgium;7. Division of Oncology, Stanford Medical Center, Stanford, CA;8. Division of Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, UT;9. Department of Oncology, University of Ulsan College of Medicine, Seoul, South Korea;10. Hematology-Oncology Division, University of Texas Southwestern Medical Center, Dallas, TX;11. Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada;12. Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea;13. British Columbia Cancer Agency-Vancouver Cancer Center, University of British Columbia, Vancouver, British Columbia, Canada;14. Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada;15. Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore;16. Department of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH;17. Department of Medical Oncology, Auckland City Hospital, Auckland, New Zealand;18. Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada;1. Charité University Medicine Berlin, Department of Urology, Berlin, Germany;2. University Medical Center Eppendorf, Department of Oncology/Hematology/Bone Marrow Transplantation/Pneumology, Hamburg, Germany;3. Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany;4. Humboldt Vivantes Hospital Berlin, Department of Urology, Berlin, Germany |
| |
| Abstract: | BackgroundTreatment of non–clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC.MethodsWe performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan–Meier method.Results91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0–13.9). Median OS was 37.9 months (95% confidence interval CI]: 21.4–46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2–10.9) and 22.9 months (95% CI: 17.8–49.2) versus 1.9 months (95% CI: 1.0–6.0) and 3.2 months (95% CI: 2.3–not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55).ConclusionWe report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS. |
| |
| Keywords: | Non–clear cell RCC Chromophobe RCC Metastatic Anti-angiogenic VEGF mTOR |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
